Deal Details
Convertible Senior Notes
Summary
Baird served as co-manager on this transaction
About
AMAG Pharmaceuticals, Inc. (“AMAG” or the “Company”) (NASDAQ-GS: AMAG) recently priced an offering of $175 million aggregate principal amount of 2.50% Convertible Senior Notes due 2019. The Company intends to use the net proceeds from the offering for working capital and other general corporate purposes.AMAG Pharmaceuticals is a rapidly growing, specialty pharmaceutical company, supported by a talented and passionate workforce. The company currently markets Feraheme® (ferumoxytol) Injection and MuGard® Mucoadhesive Oral Wound Rinse in the United States. AMAG is headquartered in Waltham, Massachuesetts.
For additional information about this transaction, please contact:
- Date
- February 2014
- Company
- AMAG Pharmaceuticals, Inc.
- Transaction
- M&A
- Sectors
- Healthcare
- Target Geography
- North America
Share
